Company: RNAC
Filing Date: 2025-10-08
Form Type: 8-K
Source: 0001453687-25-000104
Chunk: 0

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-10-08
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 2, 2025, the Board of Directors (the “ Board”) of Cartesian Therapeutics, Inc. (the “ Company”) appointed June Seymour as the Company’s Chief Accounting Officer, effective upon the commencement of Ms. Seymour’s full-time employment with the Company on October 27, 2025 (the “ Effective Date”).

Ms. Seymour, age 48, brings over two decades of financial leadership experience in the life sciences sector. She most recently served as Senior Vice President, Finance and Accounting at DNAnexus, Inc. since May 2024, and prior to that was Vice President, Finance at Neogene Therapeutics Inc., where she led her team through the company’s sale to AstraZeneca and post-acquisition integration between January 2022 and May 2024. From 2019 to 2022, Ms. Seymour held roles of increasing responsibility at Autolus Ltd., including Executive Director, Finance, and Senior Director, Financial Reporting. Earlier in her career, from 2003 to 2019, she was a Senior Manager at Ernst & Young LLP in London, specializing in U. S. transactions involving European life sciences companies. Ms. Seymour holds a Bachelor of Science in Business Administration and Accountancy from Methodist University and is a Certified Public Accountant.

In connection with Ms. Seymour’s appointment as Chief Accounting Officer of the Company, the Company entered into an employment agreement with Ms. Seymour (the “ Employment Agreement”) that will commence on the Effective Date. Under the terms of the Employment Agreement, Ms. Seymour is entitled to receive an annual base salary of $385,000 and Ms. Seymour will be eligible for an annual performance bonus targeted at 35% of her annual base salary (which, for the 2025 fiscal year, will be prorated based on the Effective Date).

If Ms. Seymour’s employment is terminated without “cause” or she resigns for “good reason,” as such terms are defined in the Employment Agreement, she shall be entitled to receive, subject to her continued compliance with a separate restrictive covenant agreement and timely execution of a separation and release agreement with the Company that includes non-competition covenants, (i) continued base salary payments for a period of six months following her termination, (ii) a pro-rata portion of her annual bonus for the year of termination,